The Africa Centres for Disease Control and Prevention (CDC) announced the launch of a trial of the antiviral smallpox drug brincidofovir for the treatment of mpox. The trial will be conducted in the Democratic Republic of the Congo in partnership with Emergent BioSolutions.
The announcement comes after yesterday’s milestone of 50,000 mpox cases across the continent. Brincidofovir has not yet been tested in double-blind, placebo-controlled studies for mpox, and there are currently no approved therapeutics to treat mpox.
Africa is not just responding to the Mpox outbreak; we are leading the charge by spearheading research and development for Mpox therapeutics.
"Africa is not just responding to the Mpox outbreak; we are leading the charge by spearheading research and development for Mpox therapeutics," said Jean Kaseya, MD, director general of the Africa CDC, in a press release. "The MpOx Study in Africa is a groundbreaking step toward developing an effective treatment that will save lives. This goes beyond research—it’s about African ownership and leadership in tackling our continent’s health challenges through essential research."
Kenya reports first cases in weeks
In related news, Kenya has reported three new mpox cases. The cases, identified in Mombasa, Nakuru, and Nairobi, come after a month without any new cases.
The continent’s current outbreak is fueled by at least two co-circulating clades of the virus being spread along multiple routes of transmission.